|
|
Logo
Logo Logo

Category Archives: "CMSC PR"

  1. Home
  2. CMSC PR
  3. Page 5
May 31, 2017
CMSC 2017 Annual Meeting – caregivers of multiple sclerosis patients say the disease exhausts physically & emotionally
CMSC PR
Most people who care for multiple sclerosis (MS) patients are happy to be caregivers, but they admit that their own emotional and physical [...]
Elizabeth Porco
Read More
...17
0
May 30, 2017
CMSC 2017 Annual Meeting – Ocrevus lowers multiple sclerosis relapse rates even further in extension study
CMSC PR
Multiple sclerosis patients who benefited from Ocrevus (ocrelizumab) in two Phase 3 clinical trials continued to benefit when they [...]
Elizabeth Porco
Read More
...19
0
May 30, 2017
CMSC 2017 Annual Meeting – physical activity halts depression in young multiple sclerosis patients, Canadian study shows
CMSC PR
Young multiple sclerosis (MS) patients who engage in physical activity can relieve symptoms of depression, concludes a Canadian study [...]
Elizabeth Porco
Read More
...17
0
May 30, 2017
CMSC 2017 Annual Meeting – Celgene’s investigational therapy Ozanimod safe, effective in treating RMS
CMSC PR, Partners
Long-term treatment for up to 12o weeks, with the investigational drug Ozanimod (RPC-1063), found to be effective and safe in patients [...]
Elizabeth Porco
Read More
...17
0
May 30, 2017
CMSC 2017 Annual Meeting – Rituxan-treated multiple sclerosis patients three times more likely to have improved brain scans
CMSC PR, Partners
Multiple sclerosis patients who start Rituxan (rituximab) treatment are three times more likely to have unchanged or improved brain-scan [...]
Elizabeth Porco
Read More
...19
0
May 30, 2017
CMSC 2017 Annual Meeting – Cladribine reduced annual multiple sclerosis relapse rate by 55% to 57%, trials show
CMSC PR
Cladribine tablets reduced relapsing multiple sclerosis patients’ annual relapse rate by 55 to 57 percent, depending on the dose, [...]
Elizabeth Porco
Read More
...16
0
May 30, 2017
CMSC 2017 Annual Meeting – review suggests certain multiple sclerosis patient groups may discontinue DMTs
CMSC PR, Partners
Older patients with secondary progressive multiple sclerosis (SPMS) as well as older relapsing patients whose MS has been inactive after [...]
Elizabeth Porco
Read More
...19
0
May 26, 2017
CMSC 2017 Annual Meeting – Tysabri improves mental outlook for patients with secondary progressive MS
CMSC PR, Partners
Long-term therapy with Tysabri (natalizumab) significantly improved the mental state of people with secondary progressive multiple [...]
Elizabeth Porco
Read More
...20
0
May 26, 2017
CMSC 2017 Annual Meeting – feeling of social stigma makes depression in multiple sclerosis more likely, study reports
CMSC PR
People with multiple sclerosis (MS) who feel stigmatized because of their condition are more likely to have depression, research presented [...]
Elizabeth Porco
Read More
...16
0
May 26, 2017
CMSC 2017 Annual Meeting – multiple sclerosis patients should contribute to outcome measure development, study argues
CMSC PR, Partners
Patients must help develop new outcome measures of multiple sclerosis (MS), since they and healthcare providers may have differing [...]
Elizabeth Porco
Read More
...20
0
  • (201) 487-1050
  • 3 University Plz Dr Ste 116, Hackensack, NJ 07601
  • info@mscare.org

CMSC provides leadership in clinical research and education; develops vehicles to share information and knowledge among members; disseminates information to the health care community and to persons affected by MS.

Contact Us
Contact Us
I have a question about
First
Last